Lung transplantation without the use of antilymphocyte antibody preparations

J. M. Kriett, C. M. Smith, A. M. Hayden, R. Robert, R. Parthasarathy, D. P. Kapelanski, S. W. Jamieson, C. R. Smith, H. Reichenspurner, B. Meyers, V. Starnes, T. M. Egan

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Survival, infection, and rejection rates and functional data are reported in 35 lung recipients treated with triple-drug immunosuppression without antilymphocytic antibody therapy. Early mortality (less than 60 days) was 6%. Thirty recipients (86%) are alive, with a mean follow-up period of 16 months (range, 1 to 36 months). Actuarial survival was 91% at 1 year and 83% at 2 years. Thirty-seven infections occurred in 24 patients. Actuarial freedom from infection was 61% at 3 months and 27% at 1 year. Only one patient died of infection (aspergillosis). Thirty-six episodes of acute rejection were treated in 23 patients. Time to first rejection was 14 ± 7.8 days. Actuarial freedom from acute rejection was 36% at 2 months. Significant functional improvement was evident in all operative survivors. Pulmonary function and exercise performance data in patients without bronchiolitis obliterans remain stable 1 year after transplantation. We conclude that the use of triple-drug immunosuppression without antilymphocytic antibody preparations in lung transplantation provides effective immunosuppression with a low risk of serious infectious complications.

Original languageEnglish
Pages (from-to)915-923
Number of pages9
JournalJournal of Heart and Lung Transplantation
Issue number6 I
StatePublished - Dec 1 1993


Dive into the research topics of 'Lung transplantation without the use of antilymphocyte antibody preparations'. Together they form a unique fingerprint.

Cite this